Literature DB >> 17872865

Rebuttal: should we avoid beta-agonists for moderate and severe chronic obstructive pulmonary disease? Yes.

Shelley R Salpeter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17872865      PMCID： PMC2234613     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  4 in total

1.  Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Authors:  Shelley R Salpeter; Nicholas S Buckley; Edwin E Salpeter
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

Review 2.  Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids.

Authors:  Shelley R Salpeter; Nicholas S Buckley
Journal:  Clin Rev Allergy Immunol       Date:  2006 Oct-Dec       Impact factor: 8.667

3.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

Review 4.  Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.

Authors:  Shelley R Salpeter
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.